-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 O7UJX0/3RLHtgy8+Q7J4moJFMdK5/b41OlzClYixyiLzuPmyoj5CHWIM20aB0New
 QRA9RWTX8XCNKzpaFDLeYw==

<SEC-DOCUMENT>0001178913-08-000239.txt : 20080129
<SEC-HEADER>0001178913-08-000239.hdr.sgml : 20080129
<ACCEPTANCE-DATETIME>20080129070238
ACCESSION NUMBER:		0001178913-08-000239
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20080129
FILED AS OF DATE:		20080129
DATE AS OF CHANGE:		20080129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		08555942

	BUSINESS ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk84775.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        F:\EDGAR Filing\Magic Software Enterprises Ltd\84774\a84774.eep  -->
     <!-- Control Number: 84774                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Magic Software Enterprises Ltd                                   -->
     <!-- Project Name:   6-K                                                              -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>6-K</TITLE>
</HEAD>
<BODY>

<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">


<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE="4"><B>FORM 6-K
<BR>SECURITIES AND EXCHANGE COMMISSION</B> </FONT></P>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Washington, D.C. 20549 </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Report of Foreign
Private Issuer </FONT></H1>

<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
<BR>for the month of January 2008</FONT></P>


<!-- MARKER FORMAT-SHEET="Head Sub 2 Left-TNR" FSL="Workstation" -->
<P ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE="5"><U><B>Compugen
Ltd.</B></U> </FONT> <BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Translation
of registrant&#146;s name in English) </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left-TNR" FSL="Workstation" -->
<P ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>72
Pinchas Rosen Street, Tel-Aviv 69512, Israel</U><BR>
(Address
of principal executive offices) </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Indicate by check mark whether the
registrant files or will file annual reports under cover Form 20-F or Form 40-F. </FONT></P>

<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Form 20-F <FONT size="3" face="Wingdings">x
</font> Form 40-F <FONT size="3" face="Wingdings">o
</font></FONT></P>



<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On January 29, 2008 Compugen Ltd.
(the &#147;Registrant&#148;) issued a Press Release, filed as Exhibit 1 to this Report on
Form 6-K, which is hereby incorporated by reference herein. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left-TNR" FSL="Workstation" -->
<P ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U><B>SIGNATURE</B></U> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized. </FONT></P>


<!-- MARKER FORMAT-SHEET="Signature (Single)" FSL="Workstation" -->
<TABLE WIDTH=100% CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=10%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Compugen Ltd.<BR>(Registrant)<BR><BR>
<BR>By: /s/ Ronit Lerner<BR>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;<BR>
Ronit Lerner<BR>Chief Financial Officer<BR>Date: January 29, 2008</FONT></TD>
</TR>
</TABLE>
<BR>

<p align=center>
<font size=2></font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">




</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        F:\EDGAR Filing\Compugen Ltd\84775\a84775.eep                    -->
     <!-- Control Number: 84775                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Compugen Ltd                                                     -->
     <!-- Project Name:   6-K                                                              -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>6-K</TITLE>
</HEAD>
<BODY>

<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">


<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Default" -->
<H1 ALIGN=right><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U><B>Exhibit 1</B></U> </FONT> </H1>

<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<IMG SRC="compugen.jpg"></FONT></P>


<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE="4"><B>Compugen Announces In-Vivo Results for Two Peptide
<BR>Anti-Inflammatory and Cardio-Protective Drug Candidates</B> </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B><I>Peptides discovered
using Compugen&#146;s GPCR ligand discovery engine</I></B> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Tel Aviv, Israel &#150; January 29,
2008 &#150; Compugen Ltd. (NASDAQ: CGEN) announced today the results from initial in-vivo
validation studies of CGEN-855A and CGEN-855B, two novel peptide agonists of the FPRL1
G-protein coupled receptor (GPCR), which may serve as anti-inflammatory and
cardio-protective drug candidates. CGEN-855A and CGEN-855B were discovered using the
Company&#146;s previously announced GPCR ligand discovery platform. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>In a study based on an in-vivo model
of acute myocardial ischemia-reperfusion injury, CGEN-855A and CGEN-855B (which is a
shorter peptide derived from CGEN-855A) were both shown to afford significant
dose-dependent protection against reperfusion injury and reduce infarct size by up to 36%.
This effect was accompanied by a dose-dependent reduction of up to 50% in plasma levels of
troponin I. Ischemia-reperfusion injury is a major contributor to infract size and
therefore plays a significant role in the long-term morbidity and mortality associated
with acute myocardial infarction (AMI). AMI is one of the most common diagnoses in
hospitalized patients in industrialized countries, with over one million new or recurrent
occurrences annually in the US alone. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>In addition to potential
cardio-protective therapeutic properties, activation of the FPRL1 pathway has recently
gained high recognition for its significance in the treatment of acute and chronic
inflammatory diseases and, in another study, both CGEN-855A and CGEN-855B showed up to 50%
inhibition of acute inflammation in a mouse air-pouch model. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#147;We are, of course, very pleased
by these successful in-vivo results for CGEN-855A and CGEN-855B which fully support
continuing the development of these peptides as anti-inflammatory and cardio-protective
drug candidates,&#148; stated Yossi Cohen, M.D., Compugen&#146;s Vice President for
Research and Development. &#147;Moreover, in view of the enormous importance of GPCRs in
the development of today&#146;s pharmacopeia, the addition of this powerful and unique
discovery engine to our growing inventory of validated engines is a major
accomplishment,&#148; Dr. Cohen continued. &#147;We look forward to our continuing use of
this engine in our own discovery activities and to additional GPCR engine-based agreements
with other companies, such as the recently announced collaboration with Merck.&#148; </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>About FPRL-1 G-Protein
Coupled Receptor</B><BR>FPRL1 (also known as ALX or ALXR)
belongs to the FPR family of GPCRs that also includes FPR1 and FPRL2. It is expressed
mainly by neutrophils and monocytes, as well as T-cells and other non-hematopoietic cell
types, and its activation promotes resolution of inflammation, leading to prominent
anti-inflammatory activity. Experiments in animal models indicate that FPRL1 agonists have
a beneficial effect in acute inflammatory conditions, such as ischemia-reperfusion injury
and organ transplantation, as well as in chronic inflammatory diseases such as
inflammatory bowel disease and asthma. </FONT> </P>

<p align=center>
<font size=2>2</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<P STYLE="page-break-after:always"></P>




<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>About Compugen&#146;s
GPCR Discovery Engine</B><BR>GPCRs are the largest family of known
drug targets, and at least 40% of prescription drugs currently available are thought to
act on GPCRs. Compugen&#146;s GPCR discovery engine, one of eight discovery engines
disclosed by Compugen to date, incorporates a proprietary model of the
&#147;peptidome&#148; &#150; an <I>in silico </I>comprehensive prediction of probable
human peptides. Through the use of a series of proprietary algorithms the engine can be
utilized to either predict GPCR ligands in general within this peptidome, or could be
directed to identify ligands of specific GPCRs of interest. In 2007, following
Compugen&#146;s validation run of the platform, 33 of the peptides predicted to be
potential ligands for GPCRs were synthesized, and of these 33, to date eight have been
shown to selectively modulate GPCRs. Included in these eight was CGEN-855. In addition to
its own discovery efforts with the platform, Compugen has recently entered into a
discovery and license option agreement with Merck &amp; Co., Inc., targeted at predicting
peptides likely to activate selected GPCRs and validating their agonistic activity. </FONT> </P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>About Compugen</B><BR>Compugen&#146;s mission is to be the
world leader in the discovery and licensing of product candidates to the drug and
diagnostic industry. Our business model focuses on maximizing the number of products in
the development pipelines of pharmaceutical and diagnostic companies worldwide under
revenue sharing licensing agreements. Our means to accomplish these objectives relies on a
growing inventory of powerful proprietary discovery engines that enable the predictive
discovery &#150; field after field &#150; of numerous therapeutic and diagnostic product
candidates. This capability is built on the Company&#146;s long-term pioneering efforts in
creating world-leading computational biology platforms, systems and tools, and in
obtaining deeper understandings of important biological phenomena at the molecular level.
Included in our growing list of collaborations are Biosite, Diagnostic Products
Corporation (a Siemens company), Medarex, Inc., Merck &amp; Co., Inc., Ortho-Clinical
Diagnostics (a Johnson &amp; Johnson company), Roche, and Teva Pharmaceutical Industries.
Compugen has established an agricultural biotechnology affiliate &#150; Evogene, and a
small-molecule drug discovery affiliate &#150; Keddem Bioscience. For additional
information, please visit Compugen&#146;s corporate Website at <U>www.cgen.com</U>. </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This press release may contain
&#147;forward-looking statements&#148; within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements include words such as &#147;may&#148;,
&#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, and
&#147;intends&#148;, and describe opinions about future events. These forward-looking
statements involve known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially different from any
future results, performance or achievements expressed or implied by such forward-looking
statements. Some of these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks relating to the
development of new products; and the ability to implement technological improvements.
These and other factors are identified and more fully explained under the heading
&#147;Risk Factors&#148; in Compugen&#146;s annual reports filed with the Securities and
Exchange Commission. </FONT></P>

<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B><I>Company contact:
</I></B><BR>Naomi Rabbie
<BR>Corporate Communications Manager
<BR>Compugen Ltd.
<BR>Email: <U>naomir@cgen.com
</U><BR>Tel: +972-52-598-9894 </FONT> </P>

<p align=center>
<font size=2>3</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>compugen.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 compugen.jpg
M_]C_X``02D9)1@`!``$`E@"6``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``0"`P,#`@0#`P,$!`0$!@H&!@4%!@P)"0<*#PT/#PX-
M#@X0$A<4$!$6$0X.%!P5%A@9&AL:$!0='QT:'Q<:&AD!!`0$!@4&#`8&#!D1
M#A$9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9
M&1D9&1D9&?_$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`&L!``,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/OZ@`H`*`"@`H`0G`H`H76NZ-:W#P7&K6$,L9PT<EPBLI]P
M3Q5*$FKI`1_\))X?_P"@YIG_`(%1_P"-/V4^S`/^$D\/_P#0<TS_`,"H_P#&
MCV4^S`JZQXW\&Z19F[U7Q;H5A;@X,UU?Q1IGTRS`54,/5F[1BW\@-FQN;>\L
MXKNTFCF@G021RQME74C(((Z@BLFK.P$M`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`$5U,(;=Y=COL4MLC7+-@=`.YI;@>5:E
M\5?%LC3VR?`OQM/;MN0/YEO&77IG'F97(_&O2C@:>C]M'\?\A'FMQX7\#SSO
M/<?L;7\TLK%WEE@LV=V/4DF3))]37I1KXB*M'%V7J_\`(FR[#/\`A$O`(_YL
MPNA_VZV7_P`73^LXG_H,_&0:=C'\9>%]$.ANG@_]C?3$U-B`DFKPVOD1CN2L
M;[F/L"OUK6CB*O-^^Q;MY-W_`!#;9'3?LQ?"`:K<7&M_$?X)?#CPZEI*GV"W
ML-'*W#NI#>:6:9U"@XP,9)R>,<\V99BX6AAZ\Y7WN]/0<;]3Z810@PHP!7SY
M0M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`8'Q
M`\;>$O`^F0:CXO\`$.GZ):7,OD137LPC5Y,%MHSU.%)_"M:.'JUI<M*+;\@/
M!/%/C#X?ZUXAN]33]KZ]TN.X<LECIUS91P6Z]E0&(G`]6))[FO;HX:O3@H_5
M;^;YO\R?F4/[<\`?]'HZ]_X'6/\`\9K3V5?_`*`U]TO\Q?,/[<\`?]'HZ[_X
M'6/_`,9I^RK_`/0&ONE_F'S/./&?Q,\$ZC'J'AZ_^,'QKUG36<PO);P6`@NT
M!ZJ3M8H?<#(]C7?1P-56J*C33\W*Z_&Q+DC`^'GA#X(^-_'&F>$=+UOXM+=:
MO-Y*M)#8QH@P2Q+*Q*C`/(!(K?$XC&8>FZLHPLO\0HI-VU/T%T6PL]*TFUTS
M3[:.VM+*);>"",86.-0%50/0``5\))N3YI;FVQ:H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`/2@#@?BBGQ-EUV"/PCX4\#:OI
MJ0AC+X@U&>"9)22&"HEO(-NW;SG)R>..>O#>P2;JRDGY+_@H3OT.:^R_'3_H
MFOPB_P#!S=?_`"%73S83_GY/[E_\D+W@^R_'3_HFWPB_\'-U_P#(5'-A/^?D
M_N7_`,D'O&'\2+/X]_\`"#:B]OH'PC\*M"BS-K(U69Q:1HP:1B)+$K@HK*2>
M@;/:MJ$L$JBYI3EY66O_`),+WCR#^T/C=_T7'X*_^#2#_P"0:];V6#_Y\U/N
M?_R1/O\`D=!\*O$GQ*T3XA:7JGC#XQ_""]T&WD)O8+35H1*8RI!*8LT.1UQN
M&<=:Y\70P\Z3C1HU%+I=:?FQKF3U/KFSGAN;6.XMI4EAF4/')&P974C(((Z@
MBOE[6T9H2T`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`<Y\2_!6B>.="CTG7/MR0PS+/')8WDMK*C@$</&P.""00>#GZ5M0Q$
MZ$N:'XI/\PL>#>/O"/PJ\(>)'T;4=$^--W(B+(MQI<FJ7D$BGNLD3,/J#@CT
MKV:%?$UH\T907KRI_B0TD8OD?!K_`*%GX_?^`>MUM;%_S4_O@+0;+:_!:2)X
MI?"OQ[DCD4J\<ECK3*RD8((/!!'8TU]<6JG3^^`:'"^.O#GPPLKR`>#O@-X_
MUFV=/WOVVQU.TDB8'C&8B&!'H<BNVC5Q4D_:UXQ]'%_J)I=$8?\`8^@C_FU_
MQG_WWJ/_`,9K?FJK_F*C_P"2_P"8M/Y3U7X(?&+Q!X"L[3PW#\"O']MX<2;Y
MOW%[=R6:'KY2O$/E!YV`],X["O+QF6PK-U/;Q<O5*_XE*36ECZSL+B.ZLXKF
M$L8YD612R%3@C(R#@CZ'FOF;6=C0FH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`K:M%=2:9<16%R+:Y>-EBF9-XC<CY6*]\'
M'%-63NPN>*B7XWQ_)-\9/ADLB?*X_LUAAAUX\[CFO7_V+_GU/[_^`(//^-?_
M`$67X9?^"YO_`(]1_L7_`#ZG]_\`P`#S_C7_`-%E^&7_`(+F_P#CU'^Q?\^I
M_?\`\`#PKXMZ-K_A?Q0W_"0?M-W5C-JI>\2VTJ;4YH(P6Y"[)VV#).%)X'3B
MO9PE2E4A:EAKI=^6_P"*,Y:=3EQJ!_Z.I\0?]^]8_P#CE=7*MOJJ_P#)?\B;
MK^8^J/V%]2>_^$NI0-\09_&RZ?K$L"ZC<0SI)$&BAE\IC,2[X,I8'.`'"C[M
M?,YQ!0KZ4^2Z6FGZ&L=M#VBO**"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`,#XC:Y?^'_``XU[I?AC4?$5T9%C6PL&17(/5BS
MD``#W]*UH4XU)\LI**[L-CY]F\(^#I9GFE_8TE>21B[NZ6)+$G))._DYKWE7
MK15HXS3UD3\AO_"&^"_^C,&_[]V/_P`73^LU_P#H,_&0QDOA+P-"FZ;]C58E
MZ;I!8*/S+T_K%?IC/QD!POB/POXO'B"[;PI^S-\.[#1V8?9H+ZW@DG"@#)=D
MN%7).>`.!CDUV4Z]+D7ML3-R\F[?*Z);ET12_P"$7^*3$)'^SI\,7=ONHE@A
M+'T`%U5>WPJU^L3^]_Y"][L?7_P.\*+X.^&VGZ3)I&B:7?.OVB^@T2V,%K]H
M?ERBEF/H,DG./PKY7%U_;57*[:Z7U=C0ZZN8`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`Z4;`<C\0OBA\/O`MU%;>+O%^E:1-.,I%<S
M`.1Z[1R!]:Z*&#KXC^%%L+I'#>-/CO\`"+6-$>PTGXWZ7H$TA&Z^LQ'),B^B
M"5&0'IR5;^H[J>4XN$KRHM^7_#"YD>>#Q/\`#8#_`)/-\6_^!-C_`/(E=WU;
M$_\`0)'[I?\`R1%O,/\`A)_AM_T>;XM_\";'_P"1*/JV)_Z!(_=+_P"2#YG&
M>*/B]X7TO57M--^.7QHUN*/@W=G'IRQ,?]DO;@L/?&*ZZ.759J\J-./D^;_Y
M(3=NIQWCOQI\./&L<$7BWQK\:]8BM26BBNFTTHC'N%$0&??&:Z\/A<3A[NE"
MFG_V]^K%==V7_A#\'OAQ\2=66U\,:?\`%EK8-MFU*XCTR.V@]<N8N3[+DU&+
MS'$82/[QT[]O>O\`F-03V/J3]G_]GCP%\)]2GU?2Q>ZMK$V574M5,;201_W(
MA&B*@/<XW'N<8`^;QV;5\8E&5E%=%_P6V7&*B>MUYA04`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`A(%`'%_$K4/BG;ZI!#X!\-^%=0M/
M+W37&M:O-;-OR?E5(X).``#DGOC'&:Z</'#M-UI->B3_`#:$[]#D9F^/LMPT
M\WPY^%$DKX#2/KET6..F2;.NI?4EHIS^Y?\`R0O>&_\`%^O^B;_";_P=W7_R
M'1?!?SS^Y?\`R0>\8/CCQI\2_!T=N?%>@_`_0C>[UMCJ/B.XB$I4#=MS:#=C
M<N<>H]:WH8>A7=J3J.V]HK_,/>/&;[Q)\5KJ\DN#^T+\(;<R,6\FUUB*.)/9
M5^RD@#W)/J2>:]F-#"Q5OJ]3YI__`"1+OW+'AMOC9X@UN#1M`^._PUU34;G)
MBM+/5HY)'P,G"BSST!J:GU*C'FJ4)I>:?_R0*_1GT%\"_AAXZTGR]5^)OCN3
M7+W!QI5I#$EG$3W9Q&KRGZ[5Y^Z<`UX.-QE&?NX:'*N[>O\`DBXIVU/6K6V@
MMH1%;PQQ(O(6-0H_(5YCUW&2CB@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`1NG%)@?)_B"+X-/XAU%[SPA\;FN6O)FF:"'4S&9#(
MVXIM?;MSG&.,8QQ7TE*>*4$HSIVMUY;_`(DZ%3R/@E_T)WQT_P"_.J__`!=:
M<^+_`)Z?WP#0/(^"7_0G?'3_`+\ZK_\`%T<^+_GI_?`-#B_B78^$+C5[5?"W
MP3^(?B*RBA):;7+C589(9&;YE12&^4A4.0>2/:NO#3JI-U:T(ORY61*VUC`M
MM!@N+J&V@_9GU\RW$BQ1A]3U)%+,0HRQ0!1DCDG`K>5?E3?UE?='_,5E_*?9
MWP(^$WA+X;:0\NBZ%;V.J7\:?;I4N)+@[@.4223YM@.<#C/7%?)8S'U<4_WC
MNEMT_!&J26QC?'']H?P!\,]3.BWDMYJ^MJ`7TW2T5V@!&0978A$[<9+8.0I%
M;8+*<1BES15H]WH$I*)YC9?MKZ,UV%NOA]J:6X.&:"_BDD`]E(49^K#ZUZ4N
M&JJ6DU^)'M$?0/PH\>>'?B)X'MO%7AF[>:RG)1TF3RY;>1?OQR*?NLIZ]0>"
M"003X6(PU3#5'2J*S1HFF>4_%']K/X=^%M:GT?0[;4/%%U:DI+/8;$M$<'!3
MSG/SD>J*R]LY!%>GALAQ-:*G*T4^^_W$N:1SF@?MI^&);Y$USP3K.GVC'#7%
MI.ET4']XIA20/]G)]`:Z)\-UDO<FF^VQ*J(]N\8?$SPQH7P:G^)L=P^J:%%:
MK=Q26&TM<HQ`4)N*C))`P2*\:CA*E2NL/:TKVU+NDKGE&@?MA_#[4]=L]-D\
M/>)-/2ZE$;WEZMJD-NO\4CD3$A5&2<`GC@$UZE3A_$0@Y\R?DK_Y$JHC)U;]
MM/PO%K+1Z7X(UN]TU7P+N6:."61<_>6)LD9Z@,5/J%/36'#=9QO*:3["]HC>
M^('[6_P]T/2].FT&TU#Q!>:C;)=&UA"PBT5OX)G;(63((VJ&(QS@$$X8?(,1
M4DU)J*6GKZ>0W-+8Z;]F[X]Z!\7+R^TJWTF\T?5[",3O:7#K(DD1.W<CKUP>
M""`1D=:YLPRNI@DI-W3Z^8XR3.0\0?MA^`=*\0ZEI!\,>*KIM-O)[)I[>.V,
M<IBD:,NF9@2I*$@D#((KKH\/8BI",^9*ZOKY_(7.BGXJ_;+\&V1MDT#PMK&K
M.\*2W!EDCMT@=E#&+/S%W4DJQ`VY'#-SBZ7#M>=^>2B)U$MCT_X"?&;PS\4_
M"M_JNE0W5A<Z.0+^PNPOF0`J2K@J2&1@K;6']U@0""!YN.R^K@YJ$];[,J,D
MU='F,_[:?P^C\S;X0\7R",L`5BM?GP<<9G[UZ2X;Q#^U'[W_`)"]HCM?C'^T
M/X8^&RZ"NMZ!K]Q/KUB+](+1("UNAQ\LFZ11NR2.,C@\UQ8/*JN*YN1I<KMK
M_P`,-R2+OP!^.GAWXLW>L1:+HFM:9'HD44L\^IK"J'>7X!21N0$R<XX(J<=E
ME3!<O.T[]F.,D]CS_P`<?MD>"=-UA[3PKH.H^)+>)BIU!95MK>7WB+`LZ_[6
MT`]02.:[J'#U><5*HU&_3J2ZB6Q(_P"V7\/8]*L;@^'/$TES<*_VBUAB@)M6
M4@`%FD4,&SE2N>`<[2,4EP[B>9KF6GGO^'02J(]*^`WQ@T/XJ:!JFM:5I6J:
M39:3*(99-4$2!CLWD@H[#`&,DD5Y^-R^>#FH2:;?8M-,\Y^(7[87P_T35)K#
MPWI>I>)?L[%6O82MO:,1P=CO\SC/\07:1R&->AA^'L14CS3:CY:W^Y$NHEL0
M>`?VQO!FK:[;Z?XD\/:EX>ANI%B2^,J7$$9/`\PKAE!.!D*0,\X'-.OP]7IQ
M<H24K=-F$9INQZ3^T%\:/#GPBL](GUO3]3U$ZU)(D$6FK$S!44,SG>ZC;\RC
M@GEA7GX'+JF,<E3:5NY4I*)P>C?MA?#>\L]1NKK1O$FG)I\"RHD\,#27<C-M
M6&)4E)+GDDG"J`2S`<UVU.'\3!Q2:=_P\WH)31F^$/VR/#&J>++/2]6\(:II
M-E>W"6ZW_P!H281%V"JTB``A<D9*EL=<$9K2KP]6A3<XS3:5[>A*J*]CZ67I
M7SYH+0!Y)\21X^T[Q;<-#\:_"WARPNV,EG8:GIL1E1``&^9I5+@-GG'<"O1H
M/#N%I4G)]T_^`)W,'^T?'O\`T<EX!_\`!=;_`/QZMO\`9_\`GQ+[W_D+7N']
MH^/?^CDO`/\`X+K?_P"/4?[/_P`^)?>_\@U[G"?'FPUC4?#T.N^)?VEK)8-%
MWX7PO$T<S"5HU.Z."XS(`57'!*@L>A-=V!J4XSY*6'U?\VVGJM!-/N6_V'M+
MTO4_B5J6MV'Q<\5^+UT:S$;66HI=PPQ/,Q"N1+(RN=L;@#'&<^E3G,Y1I1A*
MBH7=[JW3T007F>^_''Q6?`WPA\2>+8U#3:1ITUQ!&>DDP4B-3]7*C\:\3!T/
M;UX4N[2*;LC\U]!TW4O%?C2RTE[R674_$6HQP2WA.9'EFD`>3GOR3^`K]$J3
MCAZ3DEI%;',E=ZGUM^T/\`_A[JVNZ1::/XQ\+>!(])L1;-8ND2R3C/RN^75F
M.`1N;)/.2:^3P&:UJ:DYQ<[NYM*%SB?B'H[_``1_9?U71?#WCJW\0#QOJZV_
MVS3\*D4:Q8F4%6;YB$`//3BNS#S688V,YPMR+9_@*W)$\O\`V5/!%EX[^.>B
M^'M1MQ)I<(>[O(1PKQ1KD(<=BQ4''K7JYKB98?#2G%ZZ)$4XZZE#]H:VT.Q^
M.OBNQ\-645EI5I?F"WMX?N(415?;[&0.?QJ\M<WA8.H[NWZZ"DM6=SXHUB[T
MO_@G_P"%O#\DA'_"1>))F2)CS]DA>28L/]GSDB'_``,>M<-*G&>:3FOLQ_%V
M7Y7*?P&#^R+X(TGQ]\<+72?$%H+K1["RGU&\MRQ42*FU5!(YQOD0X]JWS;$S
MPN'YJ;M)NR_,5-)O4\WU6YL)M0OKS3(_+T^2>:6T3.[;`78QC/?Y-M>E34N5
M*>^E_4E^1ZE^TAX*\.>!/"/P\TW3]/6'7=1TDZAJMSO8F9FVXR"<#!+`8`X%
M>7EN)J8BI5G)^ZG9%SBDE8Z?]@P+HEWX]^(,VU8O#NAL$9NF\[I/Y(!7-GKY
M_9X=;M_\`JFK:G@-M!>7IAM+7#7U](D$.[D&61@JY_X$PS7O7C!7Z+]#+<]O
M_;?\#>#?AWK/@KP[X5T^.UN_[,GEU*0.6><AH4B>3)ZDB?!&.C>V/&R3$UL1
M&I.J[JZM^-_T+J*UBA^S)J]WX8^&/Q>\3VS*/LN@PVL8+8W3RO*L8_G3S2"J
MUJ%)]9/[M`@[)L\V^&VAMKOCSP_X<B`;[??V]K@]P74'/X9KT\35]E2G4?1,
MF.YZ9^W=K::K^T;J%E`P-OH5I!8(`>`0N]A^!?'X5YN1T>3"*3ZMLJIN,T:_
MN/"'[$NI/:2-#=?$'7C8R.G!-I%'^\&?1@FP^SFE."K9BD]J<;_,<;J&AS_[
M+?@BS^(/QST;P[JD32:6GF7E[$I(\V*,9$9(Y`9BH..V1WKIS3%2PV&E.&CV
M1--)LK?M(6'A_2OCSXITGPK8QV6E6%VMM%;Q$[4=8T$F,_\`33?59;*<L+"5
M1W;%/?0['7]5OO"?[#7A?0;626VE\?:E=ZA=E3C?:I(50`C^%T2$GV)%<=.G
M&MF4ZC^PDEZV_1W+=XPL>?\`PBOKO2/%G]LVGP_;QG]BC(^Q-8374,+M]UW6
M)6]&P&X//I7?C(J=/D=3DOUNE?[R87WL0^,-#\6ZQK>I:I!\,_$6F1WTKS+8
MV>@7@A@W<[$!CX7T%.E5HTXJ+JIVZN2_S#E=[V/0OVUM4O9O&?A'PW>2L[>'
M/#-M'*C@ADN)OFE!S_L1P?K7GY+32IU*J^U+\%_PXZNZ*GPG\&>&)?V9/B3\
M1O$VG_:KC3(QIVCLSLHBN7"JC#'4F66)><]#6F+Q558RCAZ3M?5_UZ!&*Y;L
M\_\`ASH[^(/B/X;T"/KJ6JVMN3_LF5=Y_P"^0U=^*J*G0G-]$R(J[2/U+7I7
MYJ=0M`''_&'PEX<\0>'WU#5OAWHWC.^TR-GLK'4+>%F9CC*H\H(3./H<"NG#
M8BK1E:G4<$][-_H#/&AX:T[_`*,KT3\]+_PKU_;S_P"@Q_\`DQ.O87_A&M._
MZ,KT3\]+_P`*7UB?_08__)PN^PJ>&[!&#+^Q;HJD="K:6"/TH]O/_H,?_DPM
M>QT'[)6A^-]$\3>)!XF^&WA[PCI]TL+63Z3:6\$DVUY/DF,1(8JK#!Z<MCK7
M/F=2C.,/9U')K>[;^ZXXJW0])^-O@Y/'_P`*/$'@YI_LS:O9/!%.1D12]8W(
M[@.%)'?%<&$Q#PU:-9=&4UI8^!C\//C!\.?'=CJ?_""ZP=1T:[2YM[BSLVN[
M=W4\$&/.5/O@\U]O]<P>*I./.DFMF[,YU!QU1LM\*/C9\9?B'=^(=:\,7%G=
MZFZ^=J.L0?9H($`VJ%0_/M4#A0.>>><UE''X/`4E3IRNET75^H<LI.[/H3XR
M?LZK<?LSZ)X#\%21F_\`"TGVN!IP(Q?2MN\XMCA6<NQ'8'`KP,%F[CBY5Z^T
MM'Y=ON-91TLCYE\(:)\;?AGXQ;4M#\&^)M.U4PO;&1-+:Y0HW7E0R]@0<\$"
MOI:U7!8NGRSFFO6QDE*.QT'PE_9N^)?C?7DN/$>GWGAW2YI3)=WVHX%S)DY;
M9'G.XY/+8`Z^U<V*SC#X>/+2?,TK*VPU3;>IWW[;'PZ\67VL^#O"OP_\"ZK>
M^'O"VDM!";*)3'&SLHVY+#D+$F?K7%DN,I152K7FE*3Z_/\`S+G'30J?LS_#
MWXA^"OAA\4_$5SX/U>UU^^TI-,T>R:-1.[E9"73#8QNECSR/]559EC,/7KT:
M:FN5.[?3I_D*$6DSR?PK\"_BA<Z_H^DWGP^UVQL+B]MK6>YDB39;P-*B22'#
M=%0LWX5ZE?-,-&$I1J)NSMZVT(4'<](_;*\"_$OQ?^T%J.H:'X"UR]TFRM+>
MRM9X(T,;A5+,5RPXR^.G\-<&3XO#4,*HSFDVVV7.+>PL6BZ[\,/V%O%">(-(
MN])U?Q7J\=B+>Y`5UCRHR<$\%4D_.I=2&+S*'LW>,4%N6.IXA\/-!\1>(_&%
MIIGA."276$)NK58W"L&B^<%2>,\#&>M>WB:M.E3<JNW^>AE%.^AUWB'PI\<?
MB9X_>^USPEXDO]:G5(&FO+(VT,*+D!0Q`15!)/&>23R37'3Q&"PE/EIS2COH
M[LMQDV>_>*/@!K7AG]C+4_!OAY1J?B6]O8=7U%83C[7(K)F*//94C4*#U*YZ
ML:\.GFL*N81K5-(I67EY_>S3EM&R/GSX6?#?XPOX_P!/D\,>$M>TG5;*X$D>
MH7MF88K5A_$S2#:1@G@;L]*][%8W!^Q:J333Z)ZLRC%WT#Q-\)/C1=^(M3O;
M[P+XCU2[GN9'FOC$G^E-N/[SENC8!'MBG1S'!1A%1FHJVVN@W"5]3W_Q_P#`
MZ^UC]D?P;X9MYK&P\4Z#&M^MM>2+%YK2`^="2?NM\PYZ;D&?4?/T,U5/'5*L
MM82T_P`F6X^[8\>^&7P8^/-AXL2Z\-6DWARY3,,FJIJ$(2&-OO9*ELC'.,9X
MXP>:]C$9G@)T[5'S>5B(PDCQQVDO$=K&>2[ENW/D3L69KAG;Y7)/)+$AN>>>
M>:]=6@O>5DOP\B=V?:?[4WP-UO7?@AX,TWP?;+<WW@FSCM%T_<%,\(B1"$)X
MW#8#@]>:^.RS,X4L3.=9Z3=[]G>YM.-T>!_"R[^._P`,GUK3O"G@KQ%:3:W&
MD5R9-%ED9"FX*R/C:&&]N<D<^U>YBHX#%<LJLU[M^IG%2BK(]+_9N^$GQRUO
MQC8ZQX]\8^/-%T*RD6>2TN_$EX9[T@Y";!,0JYQG/;@#FO.S',,'"FX4(1<G
MUY59?@7%2W9Q/[17P]^*WBSXY>)]?M/AYXAN;2XO"EO,L28>)`$4C+="%XKN
MR[&86AAH0=1)_P"9,XML[+Q5\._'^E_L-^'/`^E>$]7NM6UC6/[1U6QAC4O`
M@=YE63YL<2+#CD_=KAHXRA+,I5I22BE9/Y6_S&XM1L9'['/PB\=Z?^T-HVM>
M*?!^J:1IVCP7%V)[R-0CR[/*1!ACS^]9A_N5OF^84)85TZ,TV[;??^@H1:>I
M]OKT%?&HV8M,`([4`)M%+E2'<,#WHL@N&![T607`#%%A"TP$P/>E8=PP*+"%
MQQBG:P"8^HI6``,4]@`CBE8`VCWHL`;1[TPV`J/<4K`>&_ML?#7QQ\3=$T'2
M?"45DT%E<R7-R;JX\O)V[4`&.>I->QDV-HX2<IU;[6T(G&ZLCD?V//@%XT^'
MWQ6N/$WB^+3T@BT]X+7[+<^8WFNRYR,=-H-=F;9M1Q-%4Z5]];BA#E/J#;]:
M^;L:+0,4P#;]:`#;]:5@/G_]M3X":C\5Y])U_P`/36/]JZ5"]LUK?#"3Q%@P
MVO@[6!SUX(/;'/N9/FBP7-3J7Y7V)G&^QX%HO[.GQ\TBPU#2='TU],L=73R;
M^"RU988;M,$;954C>N"00>H)!X)%>[/-\#-J<W=K:ZO8S49H]8_9K_98O/#G
MC"R\6_$"]M+B?2Y1/9Z5:9>,2C[LDCG[VWJ%`QD`YX%>5F.>*M3=&@K)[ME0
MIVU9]2X`KYNQH&*+`M```HL`;?<T6`,"BP`%QZT6`6GL`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
